Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price down ...

Pfizer (PFE) ended the recent trading session at $26.86, demonstrating a -1.61% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 1.52% for ...

However, Pfizer remains highly profitable and sports a dividend yield of 6.5%, one of its highest ever. Down 57% from ...

Pfizer has reached a transition point following declines of some of its biggest blockbusters. The pharma giant is paving the way to growth through new products and acquisitions. 10 stocks we like ...

Shares of Pfizer Inc. PFE rallied 1.65% to $27.05 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 1.33% to 6,740.02 and Dow ...

If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already bought into Pfizer, and I have no plans to sell it. Here's a look at why I ...

Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its ...

Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...

Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...